Navigation Links
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION
Date:7/18/2014

NORTH CHICAGO, Ill., July 18, 2014 /PRNewswire/ -- On July 18, 2014, AbbVie issued an infographic highlighting AbbVie and Shire's complementary fit and the benefits of the proposed combination.

A copy of the infographic materials will be available on AbbVie's website at:  http://www.abbvieinvestor.com/phoenix.zhtml?c=251551&p=irol-disclaimer-documents

In accordance with Rule 30.4 of the Takeover Code, a copy of this announcement will be available on AbbVie's website at http://www.abbvieinvestor.com/phoenix.zhtml?c=251551&p=irol-disclaimer-documents.

About AbbVie

AbbVie is a global, research-based biopharmaceutical company formed in January 2013 following separation from Abbott Laboratories. The company's mission is to use its expertise, dedicated people and approach to innovation to develop and market advanced therapies that address some of the world's most complex and serious diseases. AbbVie employs approximately 25,000 people worldwide and markets medicines in more than 170 countries. AbbVie is traded on the New York Stock Exchange under "ABBV". Additional information is available on the company's website at www.abbvieinvestor.com.

The directors of AbbVie accept responsibility for the information contained in this document and, to the best of their knowledge and belief (having taken all reasonable care to ensure that such is the case), the information contained in this document is in accordance with the facts and it does not omit anything likely to affect the import of such information.

Further information

J.P. Morgan Securities LLC ("J.P. Morgan"), together with its affiliate J.P. Morgan Limited (which conducts its
'/>"/>

SOURCE AbbVie Inc.
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Star Scientific and Rock Creek Pharmaceuticals Announce the Publication of a Peer-Reviewed Article about the ASAP Clinical Trial Showing Immune System Support in Hashimotos Thyroiditis
2. BioTechniques: The International Journal of Life Science Methods Announces the Publication of the October 2013 Digital Edition Now Available Online and in the App Store
3. Celladon Corporation Announces Publication of Long Term Follow-Up Results from the MYDICAR CUPID 1 Trial in Advanced Heart Failure
4. Labome: The Gateway to the Perfect Antibody -- Labome Antibody Review Database Has Now Reached 10,000 Peer-Reviewed Formal Publications
5. New Reporting Guidelines For Case Reports Presented At The Congress On Peer Review And Biomedical Publication And Published In Seven Medical Journals
6. Mucosis Announces Publication of Data Demonstrating Safety and Protection by Mucosally Administered Mimopath®-based Prefusion-like F RSV Vaccines
7. India Pharmaceutical Sector Reviewed by Kelly Scientific Publications in In-demand Report Now Available at MarketPublishers.com
8. Signal Genetics Announces Publication of BreastPRS™ Validation Study with Weill Cornell Medical College, New York
9. China Pharmaceutical Industry Examined in New Kelly Scientific Publications Report Available at MarketPublishers.com
10. MarketResearch.com Announces Distribution of Kelly Scientific Publications
11. Rosetta Genomics Announces Acceptance for Publication by Molecular Cancer of Rosetta Cancer Origin Test Manuscript
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2015)... March 30, 2015  Naldemedine, an investigational peripherally ... Shionogi & Co., Ltd., met its primary and ... I) for the treatment of opioid-induced constipation (OIC) ... opioid therapy. Study results showed that naldemedine (0.2 ... the frequency of spontaneous bowel movement (SBM) compared ...
(Date:3/29/2015)... , March 29, 2015 Caris ... important study data showing the presence of ... gynecologic cancer samples. Using Caris Molecular Intelligence®, ... researchers identified expression of programmed cell death ... of histology while its ligand (PD-L1) expression ...
(Date:3/27/2015)... , March 27, 2015  Neogen Corporation (NASDAQ: ... adopted a prearranged trading plan in accordance with Securities ... Chairman and CEO of Neogen Corporation, is a minority ... Corporation common stock. Herbert does not have ... appropriate. The filing is only for a portion of ...
(Date:3/27/2015)... Md. , March 27, 2015  CASI Pharmaceuticals, ... to the acquisition, development and commercialization of innovative therapeutics ... global market with a commercial focus on ... three and 12 months ended December 31, 2014.  ... ($1.6 million), or ($0.05) per share, for the three ...
Breaking Biology Technology:Shionogi & Co., Ltd. Announces That Naldemedine Meets Primary Endpoint In A Phase 3 Study For The Treatment Of Opioid-Induced Constipation 2Shionogi & Co., Ltd. Announces That Naldemedine Meets Primary Endpoint In A Phase 3 Study For The Treatment Of Opioid-Induced Constipation 3Caris Life Sciences' Multiplatform Tumor Profiling Technology Identifies Expression of PD-1 and PD-L1 in Gynecologic Malignancies 2Caris Life Sciences' Multiplatform Tumor Profiling Technology Identifies Expression of PD-1 and PD-L1 in Gynecologic Malignancies 3Caris Life Sciences' Multiplatform Tumor Profiling Technology Identifies Expression of PD-1 and PD-L1 in Gynecologic Malignancies 4Neogen CEO adopts 10b5-1 Trading Plan 2CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 2CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 3CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 4CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 5CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 6
... Investment Conference on... -- HARBIN, China, Sept. 7 /PRNewswire-Asia-FirstCall/ -- ... ... --> ... { var s = ,; var first_result; // Results are keyed by longUrl, so we need ...
... Calif., Sept. 7 / PRNewswire/ -- Transdel ... announced that Transdel management will present a company overview at ... York City on Monday, September 13, 2010 at 4:05 p.m. ... webcast via the Internet by visiting the Investor Relations section ...
... Exclusive Partnership Agreements for Immunotherapy Tablets in Japan -- ANTONY, France, September 6, 2010 ... ... --> ... var s = ,; var first_result; // Results are keyed by longUrl, so we need to grab ...
Cached Biology Technology:Weikang Bio-Technology to Present at Rodman and Renshaw's Annual Global Investment Conference on September 14th 2010 2Weikang Bio-Technology to Present at Rodman and Renshaw's Annual Global Investment Conference on September 14th 2010 3Weikang Bio-Technology to Present at Rodman and Renshaw's Annual Global Investment Conference on September 14th 2010 4Weikang Bio-Technology to Present at Rodman and Renshaw's Annual Global Investment Conference on September 14th 2010 5Weikang Bio-Technology to Present at Rodman and Renshaw's Annual Global Investment Conference on September 14th 2010 6Weikang Bio-Technology to Present at Rodman and Renshaw's Annual Global Investment Conference on September 14th 2010 7Transdel Pharmaceuticals to Present at Rodman & Renshaw 12th Annual Healthcare Conference 2Transdel Pharmaceuticals to Present at Rodman & Renshaw 12th Annual Healthcare Conference 3Stallergenes and Shionogi Sign Exclusive Partnership Agreements for Immunotherapy Tablets in Japan 2Stallergenes and Shionogi Sign Exclusive Partnership Agreements for Immunotherapy Tablets in Japan 3Stallergenes and Shionogi Sign Exclusive Partnership Agreements for Immunotherapy Tablets in Japan 4Stallergenes and Shionogi Sign Exclusive Partnership Agreements for Immunotherapy Tablets in Japan 5Stallergenes and Shionogi Sign Exclusive Partnership Agreements for Immunotherapy Tablets in Japan 6Stallergenes and Shionogi Sign Exclusive Partnership Agreements for Immunotherapy Tablets in Japan 7Stallergenes and Shionogi Sign Exclusive Partnership Agreements for Immunotherapy Tablets in Japan 8Stallergenes and Shionogi Sign Exclusive Partnership Agreements for Immunotherapy Tablets in Japan 9
(Date:3/30/2015)... , Mar. 26, 2015 Research and Markets ... of the "Global Gesture Recognition Market in Automotive ... The analysts forecast the Global Gesture Recognition market in ... over the period 2013-2018. Gesture recognition is ... to different gestures of an individual. Gesture recognition technology ...
(Date:3/26/2015)... March 26, 2015 The Granite ... recreation and athletic club, today announced it has implemented ... freedom of movement for members and staff, while restricting ... comprehensive process, we selected FST,s IMID Access system because ... for our members and staff, in addition to unparalleled ...
(Date:3/24/2015)... , Mar. 24, 2015 Research and Markets ... the "Global Iris Recognition Market 2015-2019" report ... Global Iris Recognition market to grow at a CAGR ... This report covers the present scenario and the growth ... period 2015-2019. To calculate the market size, the report ...
Breaking Biology News(10 mins):Global Gesture Recognition Market in Automotive Sector Report 2015 - Growing Number of Partnerships 2Granite Club First Private Club in North America to Implement FST Biometrics Secure Access Solution, as Part of Multi-million Dollar Expansion 2Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2
... combine forces? Individuals with chronic myeloid ... as imatinib (Gleevec), which targets the protein known to ... BCR-ABL mutants emerge that are resistant to the effects ... as dasatinib (SPRYCEL), which targets BCR-ABL in a different ...
... A detailed map that pinpoints the location of every ... evolutionary steps needed to create the molecules modern version, ... at Chapel Hill and the University of Oregon. ... the proteins and other molecules necessary for life have ...
... having kids to help raise the offspring of others ... reproduce, but many African starlings have adopted this strategy ... habitats, according to a new study by University of ... the Aug. 21 issue of the journal Current Biology. ...
Cached Biology News:JCI table of contents: Aug. 16, 2007 2JCI table of contents: Aug. 16, 2007 3JCI table of contents: Aug. 16, 2007 4JCI table of contents: Aug. 16, 2007 5JCI table of contents: Aug. 16, 2007 6JCI table of contents: Aug. 16, 2007 7Structure of 450 million year old protein reveals evolution's steps 2Savanna habitat drives birds, and perhaps others, to cooperative breeding 2Savanna habitat drives birds, and perhaps others, to cooperative breeding 3Savanna habitat drives birds, and perhaps others, to cooperative breeding 4
Peptide-affinity Purified Polyclonal Antibody to ICEBERG Peptide with sequence EEDPQLASKMGLH, from C Terminus of the protein sequence according to NP_067546...
EDG-6 Lysate Source: Cell Lysate Application: Western Blotting Control Form: IgG...
3T3 cells (RSV-transformed) Source: Cell Lysate Form: Ready to Use Application: Western Blotting Control...
Madin-Darby bovine kidney (MDBK) cells Source: Cell Lysate Form: Ready to Use Application: Western Blotting Control...
Biology Products: